Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Kimmie Ng*, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Alan P. Venook, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs

*Corresponding author for this work

Research output: Contribution to journalArticle

86 Scopus citations

Abstract

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

Original languageEnglish (US)
JournalJournal of the National Cancer Institute
Volume107
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Aspirin and COX-2 inhibitor use in patients with stage III colon cancer'. Together they form a unique fingerprint.

  • Cite this

    Ng, K., Meyerhardt, J. A., Chan, A. T., Sato, K., Chan, J. A., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Benson, A. B., Schaefer, P. L., Whittom, R., Hantel, A., Goldberg, R. M., Venook, A. P., Ogino, S., Giovannucci, E. L., & Fuchs, C. S. (2015). Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. Journal of the National Cancer Institute, 107(1). https://doi.org/10.1093/jnci/dju345